CN102727648A - Chinese medicinal composition for treating vitiligo - Google Patents
Chinese medicinal composition for treating vitiligo Download PDFInfo
- Publication number
- CN102727648A CN102727648A CN201110091216XA CN201110091216A CN102727648A CN 102727648 A CN102727648 A CN 102727648A CN 201110091216X A CN201110091216X A CN 201110091216XA CN 201110091216 A CN201110091216 A CN 201110091216A CN 102727648 A CN102727648 A CN 102727648A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- fructus
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese patent medicine for treating vitiligo. The Chinese patent medicine is composed of angelica, fructus ligustri lucidi, schizonepeta, radix saposhnikoviae, Cordyceps sinensis, scorpions, safflower, polygonum multiflorum, radix rehmanniae, ligusticum wallichii, and fructus psoraleae and can be prepared into various oral dosage forms according to conventional medicine making methods. The Chinese medicinal composition of the invention has the efficacy of warming and invigorating liver and kidney, dispelling wind and eliminating dampness, regulating qi and blood, clearing channels and activating collaterals, promoting blood circulation to dissipate blood stasis, and adjusting immune function, and improving skin microcirculation, and has the characteristics of definite curative effect and convenient taking for treating and preventing vitiligo.
Description
Technical field
The present invention relates to dermatosis systemic disease treatment technology field, relate in particular to a kind of technical field of pharmaceuticals of treating leukodermic Chinese medicine composition.
Background technology
Vitiligo is a kind of common posteriority, circumscribed depigmentation dermatoses, can betide any age, is more common in child and youth.The sick limitation decolouring speckle that decreases to differing in size, clear-cut margin, on every side with the healthy skin intersection, color of the leather is denseer; Kainogenesis damages common have temporary inflammatory halo, number or single-shot or pilosity on every side, can merge each other in flakes, and the affected part hair can bleach, and does not have any subjective symptoms, and damaging part has bright gargalesthesia after the Exposure to Sunlight.Primary disease is relevant with various autoimmune property disease, like some patients with vitiligo or its relatives, can be associated with hyperthyroidism and go down, diabetes etc.; The organ specific antibody of finding thyroid, stomach, adrenal tissue in some patient's the blood exists.Primary disease often has family history, has family's genetic predisposition.In addition, with body in copper, zinc ion content lower relevant.The patient is many to increase with perspiration, the performance increase in temperature, and diseases such as bleeding time prolongation, the reason that takes place as the vitiligo disease belongs to blood deficiency and blood stasis wind-engaging person more.
At present, it is a lot of to treat this sick method and medicine, but can not reach ideal effect, Therapeutic Method such as " laser ", " skin-grafting ", " freezing " for example, and not only weak curative effect is returned skin and is stayed scar; Some medicine such as patent medicine: the speckle removing ball, remove Bai Su, white macula tincture etc.; These medicines existence take effect slowly, the course of treatment is long; Cure rate low with shortcoming such as relapse rate height; The medicine that has also has irritated and slight toxic reaction, and the medicine that also has is prone to cause side effect such as liver,kidney,spleen enlargement, brings misery to the patient.
Summary of the invention
Technical problem to be solved by this invention provides a kind of to eliminate patient's illness, and the promotion physical and mental health has the leukodermic Chinese medicine composition of treatment that the patient takes medicine conveniently, curative effect is fast, have no side effect simultaneously.
For solving the problems of the technologies described above; The present invention adopts following technical scheme: the leukodermic Chinese medicine composition of a kind of treatment, its special character is the pharmaceutical composition by the following weight proportioning: Radix Angelicae Sinensis 10-50 part, Fructus Ligustri Lucidi 10-50 part, Herba Schizonepetae 10-50 part, windproof 10-50 part, Cordyceps 5-25 part, Scorpio 5-25 part, Flos Carthami 10-50 part, Radix Polygoni Multiflori 10-50 part, Radix Rehmanniae 10-50 part, Rhizoma Chuanxiong 15-50 part, Fructus Psoraleae 5-25 part.
The preferred version of the medicine of above-mentioned weight proportion is:
The leukodermic Chinese medicine composition of above-mentioned described treatment, its special character is the pharmaceutical composition by the following weight proportioning: Radix Angelicae Sinensis 20-40 part, Fructus Ligustri Lucidi 20-40 part, Herba Schizonepetae 20-40 part, windproof 20-40 part, Cordyceps 10-20 part, Scorpio 10-20 part, Flos Carthami 20-40 part, Radix Polygoni Multiflori 20-40 part, Radix Rehmanniae 20-40 part, Rhizoma Chuanxiong 25-40 part, Fructus Psoraleae 10-20 part.
The preferred plan of the medicine of above-mentioned weight proportion is:
The leukodermic Chinese medicine composition of above-mentioned described treatment, its special character is the pharmaceutical composition by the following weight proportioning: 30 parts of Radix Angelicae Sinensis, 30 parts of Fructus Ligustri Lucidi, 30 parts of Herba Schizonepetae, windproof 30 parts, 15 parts of Cordyceps, 15 parts of Scorpios, 30 parts on Flos Carthami, 30 parts of Radix Polygoni Multiflori, 30 parts in the Radix Rehmanniae, 30 parts of Rhizoma Chuanxiong, 15 parts of Fructus Psoraleaes.
Above-mentioned described medicine is processed different oral medicine dosage forms such as pill, sublimed preparation, powder, tablet, unguentum, decoction and capsule dress powder according to the conventional technology of preparing of Chinese medicine, and above-mentioned described medicine also contains drug excipient.
Chinese medicine composition of the present invention has proper, the reasonable recipe of compatibility of drugs, and the effect of its said each herbal medicine is:
Radix Angelicae Sinensis: hot, the little hardship, warm in nature of sweet in the mouth, return liver spleen heart channel, having enriches blood invigorate blood circulation he, the effect of menstruction regulating and pain relieving, these the article diseases such as row is stagnant, menstruction regulating and pain relieving of can nourishing blood with the Rhizoma Chuanxiong compatibility;
Fructus Ligustri Lucidi: sweet-bitter flavor, cold nature, return the Liver and kidney warp, have nourishing the liver and kidney, the effect that black hair makes eye bright, these article go into Liver and kidney can benefiting essence-blood, black beard and hair, Pingyin fire, reducing the asthenic fever, is usually used in treating deficiency of the liver and kindey and causes disease;
Herba Schizonepetae: acrid in the mouth, slightly warm in nature, return lung, Liver Channel, have the diffusing wind that induces sweat, rash, the skin ulcer that disappears, hemostatic effect, be usually used in treatment flu, measles pass through send out smooth, have blood in stool, diseases such as metrorrhagia, epistaxis.
Windproof: as acrid in the mouth, sweet, slightly warm in nature, to return bladder, liver, spleen channel, have the effect of expelling pathogenic wind from the body surface, removing dampness to relieve pain, relieving convulsion, be used to treat diseases such as diseases caused by exogenous pathogenic factor exterior syndrome, rubella pruritus, rheumatic arthralgia, tetanus.
Cordyceps: sweet in the mouth, flat, warm in nature; Return swollen, kidney channel; The effect that mainly has invigorating the lung and the kidney, hemostasis and phlegm; Be usually used in treating chronic cough dyspnea due to deficiency, the chronic cough expectorant blood of lumbago due to renal deficiency, impotence and seminal emission, deficiency of both the lung and kidney, regulate body's immunity, suppress diseases such as lupus erythematosus, blood sugar lowering, antitumor.
Scorpio: acrid in the mouth, property are flat, poisonous, have relieve dizziness, high fever, infantile convulsions, epilepsy, etc., spasmolytic, analgesic effect.Be used to treat diseases such as convulsion with spasms, headache, rheumatalgia.
Flos Carthami: acrid in the mouth, warm in nature, the effect of promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain is arranged, be used for diseases such as blood circulation promoting;
Radix Polygoni Multiflori: sweetness and bitterness, puckery, slightly warm in nature is returned liver, kidney channel, has nourishing the blood and yin, loosening bowel to relieve constipation, preventing the attack (or recurrence) of malaria, dispels the wind, the antidotal effect.Cure mainly a little less than the waist knee joint acid of blood deficiency Light-headedness, cardiopalmus, insomnia, the hepatic and renal YIN deficiency; Early whitening of beard and hair, tinnitus, seminal emission, dryness of the intestine constipation; The chronic malaria body is empty; Diseases such as rubella pruritus, carbuncle sore, scrofula, hemorrhoid.
The Radix Rehmanniae: sweet-bitter flavor is cold in nature, the GUIXIN Liver and kidney through, the effect of heat clearing away YIN nourishing, cooling blood for hemostasis, YIN nourishing and the production of body fluid promoting is arranged, be usually used in epidemic febrile disease, diabetes;
Rhizoma Chuanxiong: acrid in the mouth, warm in nature, the effect of promoting flow of QI and blood, wind-expelling pain-stopping is arranged, be used to treat diseases such as menoxenia, amenorrhea dysmenorrhea 、 WEIJIA stomachache, costa sternales twinge, treating swelling and pain by traumatic injury, headache, rheumatic arthralgia;
Fructus Psoraleae: acrid in the mouth, warm in nature, nontoxic; Effect with enriching yin and nourishing kidney is usually used in that Yuanyang declines that damage, five kinds of strain and seven kinds of impairment, lumbago due to renal deficiency, kidney qi deficiency and coldness, vital essence are solid, the enuresis, spleen suffer from a deficiency of the kidney and rush down, watery diarrhea chronic dysentery, pregnant woman's lumbago, fall and weigh down diseases such as lumbago, blood stasis stagnate;
The present invention follows the principles of formulating prescriptions of the traditional Chinese medical science " monarch ", and all composition comes from the 5th edition medicine that records of China's " pharmacopeia ", and all medicines have the temperature compensation Liver and kidney mutually and altogether, the wind dehumidifying of loosing; The QI and blood regulating, is set upright and is got rid of evils dredge the meridian passage, blood circulation promoting and blood stasis dispelling, regulates immunologic function; Improve skin microcirculation, promote skin pigment to generate the effect of the white and moist skin that disappears; Treatment and prevention vitiligo, determined curative effect have no side effect various Chinese medicine preparation taking conveniences.
Clinical drug of the present invention uses the result to show to have following advantage:
1, the Chinese medicine each component selected for use of Chinese medicine composition of the present invention meets the regulation of The Drug Administration Law of People's Republic of China, utilizes the comprehensive function treatment and the prevention vitiligo of the Chinese medicine of respectively distinguishing the flavor of, and is harmless to human non-toxic.Acute toxicity test and accumulation toxicity test through white mice and rat show that underproof animal does not see any toxic reaction; Compare zero difference through anatomic observation hemogram, liver function, each organs and tissues morphology finding and matched group, prove that its safety of medicine is reliable.
2, Chinese medicine preparation of the present invention need not decoct, not have bitterness sense; Rich in proteins, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid in the medicine; Also contain various trace elements such as Saponin, plant sterol, calcium; Help absorption of human body, health invigorating, and taking convenience.
But 3, Chinese medicine preparation of the present invention efficacious therapy vitiligo not only; And it is also very obvious to leukodermic preventive effect; Particularly pass through working in coordination with each other between the medicine, strengthen medicine and treat characteristic separately, through dredge the meridian passage and adjusting immunologic function; Improve the intrinsic healthy energy of patient body and physical and mental health and life quality, reached the healing rehabilitation efficacy preferably.
Further specify medicine of the present invention to treatment therapy for vitiligo effect through the clinical practice example below.
One, clinical diagnosis standard:
Leukodermic clinical manifestation is: the skin of any department of whole body all can take place, but originates from solar radiation and the damage by friction portion of being prone to, and also can involve like the inboard mucosa of facial area, cervical region, trunk and extremity, lip, labia, glans penis and foreskin.Most of leukasmus is symmetrically distributed, and also has part patient white macula to distribute along nerve segment.Skin lesion is locality depigmentation speckle, milky, big or small from fingernail to coin, circular, oval or irregular shape.White macula place hair also can bleach.In progressive stage, the decolouring speckle is divided a word with a hyphen at the end of a line to normal skin, and development is very fast, and isomorphic response is arranged, and promptly can form the secondary vitiligo after pressure, friction, the wound.
Can divide three types according to the leukoderma scope with distributing:
1, limitation: skin lesion is confined to a position, can be divided into again: (1) segmental pattern: skin lesion is pressed dermatomere and is distributed; (2) mucosal pattern: only involve mucosa.
2, general hair style: the most common, show as skin lesion and be distributed widely in body surface, can be divided into:
(1) homeliness type: skin lesion is dispersed in and is distributed in the body surface many places;
(2) face acra type: skin lesion is distributed in face and far-end of limb;
(3) mixed type: above-mentioned several kinds of various combinations form, like face acra type+segmental pattern etc.
3, whole body type: whole skin all decolours fully or almost, also has hair to bleach.
Two, case selection
Leukodermic sickness rate is with area, the ethnic group colour of skin and different, and the dark more people's sickness rate of general colour is high more.Prevalence is about 0.1-2% in the population of China, and M-F can be fallen ill from the newborn baby about equally until old every year, but is many with teenager.Put down in writing according to interrelated data: age of onset is in the majority in 10-30 year, accounts for 62.65% of sum, and women's age of onset was than male about 5 years ahead of time.For this reason, case selection is whole cases with door rash prescription on individual diagnosis patient.
Three, curative effect determinate standard
Before the curative effect determinate standard that not have at present the promulgation of formal country, the vitiligo curative effect determinate standard that the present invention adopts (the scientific and technological publishing house of Chen Qin chief editor " research and development of Chinese medicine cosmetic health product " Chinese Medicine 1999 version the 228th page) is:
(1) recovery from illness: the white macula complete obiteration, histopathology of skin's inspection is normal;
(2) produce effects: white macula disappears more than 50%, and white macula disappearance portion of tissue pathological examination is normal;
(3) effective: white macula disappearance person accounts for the 20-50% of former white macula area, or in white macula, sees have than the polychrom island;
(4) invalid: no change or white macula enlarge before and after the treatment.
Four, clinical application method and therapeutic outcome
1, clinical application method
According to patient's sick time, the cause of disease and white macula scope and distribution situation, the component medication:
Take the capsule of embodiment 3, each 3-7 gram, every day 2-3 time, warm water delivery service, take half an hour ante cibum.Two months is a course of treatment, take continuously three the course of treatment observe the curative effect.
2, therapeutic outcome
Amount to 89 examples through clinical diagnosis treatment patients with vitiligo, male's 36 examples, women's 53 examples, the age is 12-50 year.Recovery from illness 58 examples account for 65.2% among the 89 routine patients, and produce effects 23 examples account for 25.8%, and effective 6 examples account for 7%, and invalid 2 examples account for 2%, and total effective rate reaches 98%.After treatment, the patient skin white macula disappears in various degree or fully recover, and patient do not have any untoward reaction, three big routine tests and hepatic and renal function detection do not find any unusually.Fully recover through the patient and to pay a return visit statistics, do not see an example recurrence so far.
The specific embodiment
Embodiment 1
Press the row weight portion and take by weighing each Chinese crude drug:
10 parts of Radix Angelicae Sinensis, 10 parts of Fructus Ligustri Lucidi, 10 parts of Herba Schizonepetae, windproof 10 parts, 5 parts of Cordyceps, 5 parts of Scorpios, 10 parts on Flos Carthami, 10 parts of Radix Polygoni Multiflori, 10 parts in the Radix Rehmanniae, 15 parts of Rhizoma Chuanxiong, 5 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed sublimed preparation according to the pharmaceutical methods that routine prepares sublimed preparation.
Embodiment 2
Press the row weight portion and take by weighing each medical material:
50 parts of Radix Angelicae Sinensis, 50 parts of Fructus Ligustri Lucidi, 50 parts of Herba Schizonepetae, windproof 50 parts, 25 parts of Cordyceps, 25 parts of Scorpios, 50 parts on Flos Carthami, 50 parts of Radix Polygoni Multiflori, 50 parts in the Radix Rehmanniae, 50 parts of Rhizoma Chuanxiong, 25 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed packed powder according to the pharmaceutical methods that routine prepares powder.
Embodiment 3
Press the row weight portion and take by weighing each medical material:
20 parts of Radix Angelicae Sinensis, 20 parts of Fructus Ligustri Lucidi, 20 parts of Herba Schizonepetae, windproof 20 parts, 10 parts of Cordyceps, 10 parts of Scorpios, 20 parts on Flos Carthami, 20 parts of Radix Polygoni Multiflori, 20 parts in the Radix Rehmanniae, 25 parts of Rhizoma Chuanxiong, 10 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed capsule according to the pharmaceutical methods that routine prepares capsule.
Embodiment 4
Press the row weight portion and take by weighing each medical material:
40 parts of Radix Angelicae Sinensis, 40 parts of Fructus Ligustri Lucidi, 40 parts of Herba Schizonepetae, windproof 40 parts, 20 parts of Cordyceps, 20 parts of Scorpios, 40 parts on Flos Carthami, 40 parts of Radix Polygoni Multiflori, 40 parts in the Radix Rehmanniae, 40 parts of Rhizoma Chuanxiong, 20 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed tablet according to the pharmaceutical methods that routine prepares tablet; (like conventional tablet, sugar coated tablet, film coated tablet etc.), and give conventional drug excipient (like starch, sucrose, lactose, calcium stearate, magnesium stearate etc.).
Embodiment 5
Press the row weight portion and take by weighing each medical material:
35 parts of Radix Angelicae Sinensis, 35 parts of Fructus Ligustri Lucidi, 35 parts of Herba Schizonepetae, windproof 35 parts, 10 parts of Cordyceps, 10 parts of Scorpios, 25 parts on Flos Carthami, 25 parts of Radix Polygoni Multiflori, 25 parts in the Radix Rehmanniae, 30 parts of Rhizoma Chuanxiong, 15 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed pill according to the pharmaceutical methods that routine prepares pill, and give conventional drug excipient.
Embodiment 6
Press the row weight portion and take by weighing each medical material:
30 parts of Radix Angelicae Sinensis, 30 parts of Fructus Ligustri Lucidi, 30 parts of Herba Schizonepetae, windproof 30 parts, 15 parts of Cordyceps, 15 parts of Scorpios, 30 parts on Flos Carthami, 30 parts of Radix Polygoni Multiflori, 30 parts in the Radix Rehmanniae, 30 parts of Rhizoma Chuanxiong, 15 parts of Fructus Psoraleaes.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is processed granule according to the pharmaceutical methods that routine prepares granule.
Claims (5)
1. the leukodermic Chinese medicine composition of treatment is characterized in that the pharmaceutical composition by the following weight proportioning: Radix Angelicae Sinensis 10-50 part, Fructus Ligustri Lucidi 10-50 part, Herba Schizonepetae 10-50 part, windproof 10-50 part, Cordyceps 5-25 part, Scorpio 5-25 part, Flos Carthami 10-50 part, Radix Polygoni Multiflori 10-50 part, Radix Rehmanniae 10-50 part, Rhizoma Chuanxiong 15-50 part, Fructus Psoraleae 5-25 part.
2. the leukodermic Chinese medicine composition of treatment according to claim 1 is characterized in that the pharmaceutical composition by the following weight proportioning: Radix Angelicae Sinensis 20-40 part, Fructus Ligustri Lucidi 20-40 part, Herba Schizonepetae 20-40 part, windproof 20-40 part, Cordyceps 10-20 part, Scorpio 10-20 part, Flos Carthami 20-40 part, Radix Polygoni Multiflori 20-40 part, Radix Rehmanniae 20-40 part, Rhizoma Chuanxiong 25-40 part, Fructus Psoraleae 10-20 part.
3. the leukodermic Chinese medicine composition of treatment according to claim 1 is characterized in that the pharmaceutical composition by the following weight proportioning: 30 parts of Radix Angelicae Sinensis, 30 parts of Fructus Ligustri Lucidi, 30 parts of Herba Schizonepetae, windproof 30 parts, 15 parts of Cordyceps, 15 parts of Scorpios, 30 parts on Flos Carthami, 30 parts of Radix Polygoni Multiflori, 30 parts in the Radix Rehmanniae, 30 parts of Rhizoma Chuanxiong, 15 parts of Fructus Psoraleaes.
4. according to the leukodermic Chinese medicine composition of the described treatment of arbitrary claim in the claim 1 to 3, it is characterized in that described medicine processes different oral medicine dosage forms such as pill, sublimed preparation, powder, tablet, unguentum, decoction and capsule dress powder according to the conventional technology of preparing of Chinese medicine.
5. the leukodermic Chinese medicine composition of treatment according to claim 4 is characterized in that described medicine also contains drug excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110091216XA CN102727648A (en) | 2011-03-31 | 2011-03-31 | Chinese medicinal composition for treating vitiligo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110091216XA CN102727648A (en) | 2011-03-31 | 2011-03-31 | Chinese medicinal composition for treating vitiligo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727648A true CN102727648A (en) | 2012-10-17 |
Family
ID=46984412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110091216XA Pending CN102727648A (en) | 2011-03-31 | 2011-03-31 | Chinese medicinal composition for treating vitiligo |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727648A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069190A (en) * | 2014-05-13 | 2014-10-01 | 李宏广 | Traditional Chinese medicament for treating leukoderma |
| CN104368035A (en) * | 2013-08-13 | 2015-02-25 | 凌峰 | Biological dressing for eliminating white spots and scars on human body |
| CN104721367A (en) * | 2015-03-05 | 2015-06-24 | 淄博夸克医药技术有限公司 | Traditional Chinese medicine for treating leucoderma |
| CN105902722A (en) * | 2016-05-05 | 2016-08-31 | 王保安 | Traditional Chinese medicine composition for treating leucoderma and preparation method and application thereof |
-
2011
- 2011-03-31 CN CN201110091216XA patent/CN102727648A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104368035A (en) * | 2013-08-13 | 2015-02-25 | 凌峰 | Biological dressing for eliminating white spots and scars on human body |
| CN104069190A (en) * | 2014-05-13 | 2014-10-01 | 李宏广 | Traditional Chinese medicament for treating leukoderma |
| CN104721367A (en) * | 2015-03-05 | 2015-06-24 | 淄博夸克医药技术有限公司 | Traditional Chinese medicine for treating leucoderma |
| CN105902722A (en) * | 2016-05-05 | 2016-08-31 | 王保安 | Traditional Chinese medicine composition for treating leucoderma and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102416079A (en) | Chinese patent medicine for treating leucoderma | |
| CN103251867A (en) | Chinese herbal compound medicine for treating diabetes mellitus and preparation method thereof | |
| CN102362950A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
| CN102362919A (en) | Traditional Chinese medicine for treating scleroderma | |
| CN102727648A (en) | Chinese medicinal composition for treating vitiligo | |
| CN103432559A (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN102430013A (en) | Chinese medicine for treating vitiligo | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN102302733B (en) | Oral Chinese medicinal composition for treating ovarian cyst | |
| CN102423433A (en) | Traditional Chinese drug mixture for treating psoriasis | |
| CN102406866A (en) | Chinese medicinal composition for treating psoriasis | |
| CN102579975B (en) | Traditional Chinese medicine mixture for treating psoriasis | |
| CN102198202B (en) | Pills for treating gout | |
| CN100415288C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN102406865A (en) | Chinese medicinal composition for treating psoriasis | |
| CN102406893A (en) | Chinese patent medicine for treating psoriasis. | |
| CN102579895B (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN105125911A (en) | Traditional Chinese medicinal composition for regulating and treating benign prostatic hyperplasia and preparation method of traditional Chinese medicinal composition | |
| CN102423458A (en) | Chinese patent medicine for treating psoriasis | |
| CN102406913A (en) | Chinese medicinal composition for treating melancholia | |
| CN102416099A (en) | Traditional Chinese medicine for treating psoriasis | |
| CN102641381A (en) | Chinese patent medicine for treating acute urticaria | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121017 |